

**Supplementary Table 1. Approved and emerging novel therapeutic agents for various kidney diseases**

Medications (class)	Conditions	Status	Clinical trials
Inaxaplin (APOL1 inhibitor)	Two APOL1 variants FSGS	Emerging	NCT04340362
Sparsentan (endothelin A receptor antagonist)	FSGS	Emerging	DUPLEX (NCT03493685)
	IgAN	Approved	PROTECT (NCT03762850)
Budesonide (corticosteroid)	IgAN	Approved	NEFIGARD (NCT03643965)
Atrasentan (endothelin A receptor antagonist)	IgAN	Emerging	ALIGN (NCT04573478)
Sibeprenlimab (APRIL inhibitor)	IgAN	Emerging	VISIONARY (NCT05248646)
Narsoplimab (MASP-2 inhibitor)	IgAN	Emerging	ARTEMIS-IgAN (NCT02682407)
Iptacopan (factor B inhibitor)	IgAN	Emerging	APPLAUSE-IgAN (NCT04578834)
	aHUS	Emerging	APPELHUS (NCT04889430)
Ravulizumab (long acting anti-C5 monoclonal antibody)	aHUS	Approved	ALXN1210-aHUS311 (NCT02949128)
Dapagliflozin/empagliflozin (SGLT2-i)	CKD/DKD	Approved	DAPA-CKD (NCT03036150)
			EMPA-kidney (NCT03594110)
Canagliflozin (SGLT2-i)	DKD	Approved	CREDENCE (NCT02065791)
Finerenone (non-steroidal mineralocorticoid receptor antagonists)	DKD	Approved	FIGARO-DKD (NCT02545049)
			FIDELIO-DKD (NCT02540993)
Ziltivekimab (antibody mediated IL-6 inhibition)	CKD	Emerging	FIND-CKD (NCT05047263)
	CKD	Emerging	RESCUE (NCT03926117)
Semaglutide (GLP-1 receptor agonist)	Atherosclerotic CVD in CKD	Emerging	RESCUE II (NCT04626505)
			ZEUS (NCT05021835)
Voclosporin (calcineurin inhibitor)	DKD	Approved	FLOW (NCT03819153)
Voclosporin (calcineurin inhibitor)	Lupus nephritis	Approved	AURORA1/2 (NCT03021499)
Belimumab (anti-BAFF monoclonal antibody)	Lupus nephritis	Approved	BLISS-LN (NCT01639339)
Anifrolumab (anti-interferon $\alpha$ antibody)	Lupus nephritis	Emerging	IRIS (NCT05138133)
Daratumumab (anti-CD38 monoclonal antibody)	Lupus nephritis	Emerging	NCT04868838
Avacopan (C5a receptor antagonist)	ANCA vasculitis	Approved	ADVOCATE (NCT02994927)

aHUS, atypical hemolytic uremic syndrome; APOL1, apolipoprotein L1; ANCA, anti-neutrophil cytoplasmic antibody; CKD, chronic kidney disease; CVD, cardiovascular disease; DKD, diabetic kidney disease; FSGS, focal segmental glomerulosclerosis; GLP-1, glucagon-like peptide-1; IgAN, IgA nephropathy; IL, interleukin; MASP-2, mannan-binding lectin-associated serine protease-2; SGLT2-i, sodium-glucose cotransporter 2 inhibitors.